Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Here, we discovered that carriers of both variants, AKAP10 Ile646Val and AKAP13 Lys526Gln, are at a further enhanced breast cancer risk (OR=2.41, 95% CI 1.30-4.46, P=0.005).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP763613.RAonCA54baVsoKNCoMs2UFSynAyIQsQLciNzZnnFgdGPE130_assertion description "[Here, we discovered that carriers of both variants, AKAP10 Ile646Val and AKAP13 Lys526Gln, are at a further enhanced breast cancer risk (OR=2.41, 95% CI 1.30-4.46, P=0.005).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP763613.RAonCA54baVsoKNCoMs2UFSynAyIQsQLciNzZnnFgdGPE130_provenance.
• NP465453.RAXkQY4b7jQeSCNe6jWTqcSAA5vXJxkFU_1tQpJ_a0PiY130_assertion description "[Here, we discovered that carriers of both variants, AKAP10 Ile646Val and AKAP13 Lys526Gln, are at a further enhanced breast cancer risk (OR=2.41, 95% CI 1.30-4.46, P=0.005).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP465453.RAXkQY4b7jQeSCNe6jWTqcSAA5vXJxkFU_1tQpJ_a0PiY130_provenance.
• NP875951.RA99NjpVpgzMBcRjvk85ZBrLXSz-sQWJTS5ficDtJBc6U130_assertion description "[Here, we discovered that carriers of both variants, AKAP10 Ile646Val and AKAP13 Lys526Gln, are at a further enhanced breast cancer risk (OR=2.41, 95% CI 1.30-4.46, P=0.005).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP875951.RA99NjpVpgzMBcRjvk85ZBrLXSz-sQWJTS5ficDtJBc6U130_provenance.
• NP556389.RAPQWPDbVSTE7a0GIwGr2iZYK4yYrutjRb2JzVw00qnzA130_assertion description "[Here, we discovered that carriers of both variants, AKAP10 Ile646Val and AKAP13 Lys526Gln, are at a further enhanced breast cancer risk (OR=2.41, 95% CI 1.30-4.46, P=0.005).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP556389.RAPQWPDbVSTE7a0GIwGr2iZYK4yYrutjRb2JzVw00qnzA130_provenance.
• assertion description "[Here, we discovered that carriers of both variants, AKAP10 Ile646Val and AKAP13 Lys526Gln, are at a further enhanced breast cancer risk (OR=2.41, 95% CI 1.30-4.46, P=0.005).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Here, we discovered that carriers of both variants, AKAP10 Ile646Val and AKAP13 Lys526Gln, are at a further enhanced breast cancer risk (OR=2.41, 95% CI 1.30-4.46, P=0.005).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Here, we discovered that carriers of both variants, AKAP10 Ile646Val and AKAP13 Lys526Gln, are at a further enhanced breast cancer risk (OR=2.41, 95% CI 1.30-4.46, P=0.005).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Here, we discovered that carriers of both variants, AKAP10 Ile646Val and AKAP13 Lys526Gln, are at a further enhanced breast cancer risk (OR=2.41, 95% CI 1.30-4.46, P=0.005).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Here, we discovered that carriers of both variants, AKAP10 Ile646Val and AKAP13 Lys526Gln, are at a further enhanced breast cancer risk (OR=2.41, 95% CI 1.30-4.46, P=0.005).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP102500.RAfz5m2lUuj9Rxy0ZXFRboPRT0_RU4antli21ENKHi4Jg130_assertion description "[Here, we discovered that carriers of both variants, AKAP10 Ile646Val and AKAP13 Lys526Gln, are at a further enhanced breast cancer risk (OR=2.41, 95% CI 1.30-4.46, P=0.005).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP102500.RAfz5m2lUuj9Rxy0ZXFRboPRT0_RU4antli21ENKHi4Jg130_provenance.
• NP568090.RAerRV0fexqW_CWxSrHjrcmiqldRXLA71bPV8HPxMaK5U130_assertion description "[Here, we discovered that carriers of both variants, AKAP10 Ile646Val and AKAP13 Lys526Gln, are at a further enhanced breast cancer risk (OR=2.41, 95% CI 1.30-4.46, P=0.005).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP568090.RAerRV0fexqW_CWxSrHjrcmiqldRXLA71bPV8HPxMaK5U130_provenance.
• NP863254.RAkd4KL6G7z6nlljedVMwniHAypsP4p4LehMvzxYi0SI0130_assertion description "[Here, we discovered that carriers of both variants, AKAP10 Ile646Val and AKAP13 Lys526Gln, are at a further enhanced breast cancer risk (OR=2.41, 95% CI 1.30-4.46, P=0.005).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP863254.RAkd4KL6G7z6nlljedVMwniHAypsP4p4LehMvzxYi0SI0130_provenance.
• NP82546.RADFmFIZvmM7nk23QvcoblKJjjWLkqBsI1XV32_hN-G10130_assertion description "[Here, we discovered that carriers of both variants, AKAP10 Ile646Val and AKAP13 Lys526Gln, are at a further enhanced breast cancer risk (OR=2.41, 95% CI 1.30-4.46, P=0.005).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP82546.RADFmFIZvmM7nk23QvcoblKJjjWLkqBsI1XV32_hN-G10130_provenance.
• NP568091.RApRid5ZUbudxhYTAu6_2CKDCOiXU4tdpQLMysV7bj58k130_assertion description "[Here, we discovered that carriers of both variants, AKAP10 Ile646Val and AKAP13 Lys526Gln, are at a further enhanced breast cancer risk (OR=2.41, 95% CI 1.30-4.46, P=0.005).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP568091.RApRid5ZUbudxhYTAu6_2CKDCOiXU4tdpQLMysV7bj58k130_provenance.
• NP568088.RA0kqlchinxEw46fGenv-FIAC6UoZm5v5_E-qXFibsrjE130_assertion description "[Here, we discovered that carriers of both variants, AKAP10 Ile646Val and AKAP13 Lys526Gln, are at a further enhanced breast cancer risk (OR=2.41, 95% CI 1.30-4.46, P=0.005).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP568088.RA0kqlchinxEw46fGenv-FIAC6UoZm5v5_E-qXFibsrjE130_provenance.
• NP568092.RA_WyFIee7dAmq4BL11KgzQTU1-jII6RGBN2YMGUgOBjU130_assertion description "[Here, we discovered that carriers of both variants, AKAP10 Ile646Val and AKAP13 Lys526Gln, are at a further enhanced breast cancer risk (OR=2.41, 95% CI 1.30-4.46, P=0.005).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP568092.RA_WyFIee7dAmq4BL11KgzQTU1-jII6RGBN2YMGUgOBjU130_provenance.
• NP863217.RAx7bSk-6b85OQnMQhDCwpRi9DwkRmgG5kCXZrd0tEgYM130_assertion description "[Here, we discovered that carriers of both variants, AKAP10 Ile646Val and AKAP13 Lys526Gln, are at a further enhanced breast cancer risk (OR=2.41, 95% CI 1.30-4.46, P=0.005).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP863217.RAx7bSk-6b85OQnMQhDCwpRi9DwkRmgG5kCXZrd0tEgYM130_provenance.
• NP863239.RA70k-AlGWutv50LjusaTyEBlOHOZ9P9JMzKkdjHc-3xU130_assertion description "[Here, we discovered that carriers of both variants, AKAP10 Ile646Val and AKAP13 Lys526Gln, are at a further enhanced breast cancer risk (OR=2.41, 95% CI 1.30-4.46, P=0.005).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP863239.RA70k-AlGWutv50LjusaTyEBlOHOZ9P9JMzKkdjHc-3xU130_provenance.
• NP863248.RA6j09vP62fSagenA9M0rUVjCdz6o53u49bMf_86I7WNE130_assertion description "[Here, we discovered that carriers of both variants, AKAP10 Ile646Val and AKAP13 Lys526Gln, are at a further enhanced breast cancer risk (OR=2.41, 95% CI 1.30-4.46, P=0.005).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP863248.RA6j09vP62fSagenA9M0rUVjCdz6o53u49bMf_86I7WNE130_provenance.